Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates.

نویسندگان

  • José Bagán
  • Juan Blade
  • Jose Manuel Cozar
  • Manuel Constela
  • Ramón García Sanz
  • Francisco Gómez Veiga
  • Juan José Lahuerta
  • Ana Lluch
  • Bartomeu Massuti
  • Juan Morote
  • Jesús F San Miguel
  • Eduardo Solsona
چکیده

(1) Stomatology Professor, Valencia School of Medicine, and Head of the Stomatology Service in the Valencia General Hospital (2) Senior Consultant in Hematology, Barcelona Clinical Hospital (3) Urology Registrar, Urology Service, Granada “Virgen de las Nieves” Hospital (4) Head of the Medical Oncology Service in the Pontevedra “Montecelo” Hospital (5) Hematology Registrar, Hematology Service, Salamanca University Hospital (6) Urology Service Registrar, A Coruña “Juan Canalejo” Hospital (7) Head of the Hematology Service, Madrid “Doce de Octubre” University Hospital (8) Oncology Professor, Hematology and Medical Oncology Service, Valencia Clinical University Hospital (9) Head of the Medical Oncology Service, Alicante General Hospital (10) Head of the Urology Service, Barcelona “Valle Hebrón” Hospital (11) Head of the Hematology Service, Salamanca Clinical University Hospital (12) Head of the Urology Service, Valencia Institute of Oncology (IVO)

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.

PURPOSE This article discusses osteonecrosis of the jaw (ONJ) and offers health care professionals practical guidelines and recommendations for the prevention, diagnosis, and management of ONJ in cancer patients receiving bisphosphonate treatment. METHODS A panel of experts representing oral and maxillofacial surgery, oral medicine, endocrinology, and medical oncology was convened to review t...

متن کامل

[Osteonecrosis of the jaw].

The paper concerns osteonecrosis of the jaw (ONJ). It is a rare but serious clinical condition. It can develop in patients treated in oncologic doses with bisphosphonates but also with denosumab. In osteoporosis ONJ seems to be very rare. Definition, pathogenesis, risk factors, prevention and treatment, and the frequency of ONJ are presented.

متن کامل

Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role

Several recent reports have described osteonecrosis of the jaws (ONJ) associated with the use of bisphosphonates. Rheumatologists treating bone diseases with bisphosphonate need, therefore, to be aware of this potential risk and plan the prophylaxis, early diagnosis and prevention of potential consequences. We review the literature on this newly described complication, with particular focus on ...

متن کامل

Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark

Osteonecrosis of the jaw (ONJ) is an adverse effect of bone-targeted therapies, which are used to prevent symptomatic skeletal events following bone malignancy. We examined the association between ONJ and survival among cancer patients treated with bone-targeted agents. Using nationwide registries and databases in Denmark, we identified 184 cancer patients with incident ONJ between 2010 and 201...

متن کامل

A rare case of osteonecrosis of the jaw related to imatinib

Osteonecrosis of the jaw (ONJ) is commonly described as an adverse effect of the use of bisphosphonates. A few cases of ONJ associated with tyrosine kinase inhibitors (sunitinib, imatinib) have been reported in the literature and usually they occurred in patients simultaneously treated with bisphosphonates. We report an atypical case of ONJ related only to imatinib. A 72-year-old male patient w...

متن کامل

Osteonecrosis of the jaw: who gets it, and why?

Osteonecrosis of the jaw (ONJ) is now defined by the presence of exposed bone in the mouth, which fails to heal after appropriate intervention over a period of six or eight weeks. It is commonly precipitated by a tooth extraction in patients treated with zoledronate, pamidronate or a combination of these agents, for the management of myeloma, breast cancer or prostate cancer. In patients with t...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Medicina oral, patologia oral y cirugia bucal

دوره 12 4  شماره 

صفحات  -

تاریخ انتشار 2007